This case highlights right-sided heart failure and severe pulmonary hypertension as a rare but serious complication of doxorubicin therapy requiring close cardiovascular monitoring.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to pulmonary hypertension risk despite doxorubicin surveillance; extends cardiotoxicity spectrum beyond LV dysfunction.
We present a 58-year-old woman with metastatic lobular carcinoma on long-term doxorubicin with appropriate cardiovascular surveillance presenting with dyspnea and orthopnea. An echocardiogram and right heart catheterization revealed severe pulmonary hypertension and acute right heart failure. Her cumulative doxorubicin dose was 1.145 g/m2. Doxorubicin was withdrawn and guideline-directed medical therapy and antipulmonary hypertensive therapy was started. A follow-up right heart catheterization showed a recovered cardiac output and improved variables. This case highlights the importance of considering right-sided heart failure as a rare but serious complication in patients receiving doxorubicin, which warrants closer cardiovascular monitoring.
No takes yet. Share an insight, caveat, or question.
Saravia et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: